End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
32.62 ZAR | -1.09% | +5.23% | +6.29% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- With regards to fundamentals, the enterprise value to sales ratio is at 0.86 for the current period. Therefore, the company is undervalued.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company does not generate enough profits, which is an alarming weak point.
- With a 2024 P/E ratio at 27.73 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The company appears highly valued given the size of its balance sheet.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+6.29% | 1.51B | C | ||
-32.86% | 14.96B | B- | ||
-23.15% | 11.07B | B | ||
+9.74% | 6.13B | C | ||
-22.64% | 6.08B | B | ||
-10.91% | 5.98B | C+ | ||
+0.88% | 4.76B | D- | ||
+53.60% | 4.36B | - | C | |
-10.49% | 3.73B | B | ||
-12.53% | 3.43B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DCP Stock
- Ratings Dis-Chem Pharmacies Limited